Drug Profile
ATX 201
Alternative Names: ATX-201Latest Information Update: 21 Jul 2010
Price :
$50
*
At a glance
- Originator Novartis
- Developer Kythera Biopharmaceuticals
- Class Skin disorder therapies
- Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Actinic keratosis
Most Recent Events
- 26 Jun 2007 Phase-II clinical trials in Actinic keratosis in France (Topical)